高胆固醇血症导致微质功能障碍,并削弱对粉样质斑块的反应
Sarah Kaye1, Andrew Gold2, Da Lin1
1Department of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Experimental neurology
|April 26, 2025
概括
在阿尔茨海默氏症 (AD) 模型中,高胆固醇会损害大脑免疫细胞 (微细胞),恶化粉样质斑块和认知衰退. 管理胆固醇可能会减缓AD的进展.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 高胆固醇血症与阿尔茨海默病 (AD) 有关,但其对AD病理,微质功能和粉样β (Aβ) 动态的确切影响尚未完全理解.
- 研究遗传倾向,饮食和AD进展之间的相互作用对于了解疾病机制至关重要.
研究的目的:
- 阐明高胆固醇血症和阿尔茨海默氏病 (AD) 病理学之间的机械联系.
- 在AD小鼠模型中检查高胆固醇血症对微质功能和粉样β (Aβ) 动态的影响.
主要方法:
- 使用APP (AK) 和APP (NL-G-F);LDLR (AL) 控制下的小鼠模型和西方饮食 (WD) 诱导高胆固醇.
- 在微质上进行RNA测序和脂质组分析,以评估功能和代谢变化.
- 进行行为分析以评估认知表现和类似焦虑的行为.
主要成果:
- 高胆固醇血症抑制了Aβ斑块周围的微质聚类和激活,减少了斑块的紧性.
- RNA测序揭示了微质线粒体功能受损,蛋白质合成减少和神经炎症增加.
- 脂质组分析显示了亲炎性微质脂质组,行为测试表明认知功能受损和焦虑增加.
结论:
- 高胆固醇血症通过破坏微质功能,改变脂质代谢和损害认知功能来加剧AD病理.
- 高胆固醇血症的药理管理可能是减缓AD进展的治疗策略.
相关概念视频
01:26Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
03:03Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K
01:38Inflammation
51.0K
Overview
51.0K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
557
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
557